## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.6% in upper entry zone (3.0-6.0%), top 10% cross-sectional ranking. Short-term MRS_5 (4.2%) confirms momentum alignment. Strong momentum (+3.0% 5-day acceleration). Outperforming sector by 7.1%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($33.40)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?**
- Source: Yahoo Finance | 20251204T103000 | Somewhat-Bearish | Relevance: 100%
- Ultragenyx (RARE) shares have increased by 14.4% since its last earnings report, outperforming the S&P 500. Despite missing Q3 2025 earnings and sales estimates, the company reported a 15% year-over-year revenue increase and reaffirmed its 2025 financial guidance. Investors are now watching if this positive trend will continue given downward revisions in analyst estimates.

**2. Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251203T130921 | Somewhat-Bearish | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 108.1% in the second quarter, now owning 67,720 shares valued at approximately $2.46 million. Other institutional investors also boosted their holdings, with institutional ownership of Ultragenyx now standing at about 97.67%. Despite a "Moderate Buy" consensus rating and an average price target of $80.23, Ultragenyx recently missed Q3 earnings and revenue estimates, and its stock trades well below the target at around $33.37.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.3B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 2.5% to 5.6% (+3.0% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 90th percentile. MRS_5 at 4.2% confirms short-term momentum alignment. Outperforming sector by 7.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.59% (CS: 90) | Strong |
| RSI_14 | 63.7 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.102x | Above |
| vs SMA50 | 1.120x | Above |
| vs SMA200 | 1.077x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $36.54
- **Stop Loss:** $33.40 (8.6% risk)
- **Target:** $41.25 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 159
- **Position Value:** $5,809.86
- **Portfolio %:** 5.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*